A product focused pharmaceutical company.
Theraly is a product focused pharmaceutical company with a goal to efficiently generate medically important, stable, and long-acting therapies. Theraly enables products using its proprietary platform technology that can empower short-acting peptides and proteins by dramatically increasing their half-lives while maintaining potency. Their lead program is a preclinical stage product in development for organ fibrosis. TLY012, has shown therapeutic efficacy in a number of pre-clinical models of organ fibrosis, autoimmune/inflammatory conditions, and in oncology.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Mar 21, 2018 | Seed | $200K | 1 | TEDCO | — | Detail |